353 related articles for article (PubMed ID: 7692684)
21. Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization.
Feltkamp MC; Vierboom MP; Toes RE; Ossendorp F; ter Schegget J; Melief CJ; Kast WM
Immunol Lett; 1995; 47(1-2):1-8. PubMed ID: 8537084
[TBL] [Abstract][Full Text] [Related]
22. Endogenous presentation of a nascent antigenic epitope to CD8+ CTL is more efficient than exogenous presentation.
Hahn YS; Hahn CS; Braciale TJ
Immunol Cell Biol; 1996 Oct; 74(5):394-400. PubMed ID: 8912001
[TBL] [Abstract][Full Text] [Related]
23. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
[TBL] [Abstract][Full Text] [Related]
24. Interaction of in vitro- and in vivo-generated cytotoxic T cells with SV40 T antigen: analysis with synthetic peptides.
Alsheikhly AR
Scand J Immunol; 1994 May; 39(5):467-79. PubMed ID: 8191222
[TBL] [Abstract][Full Text] [Related]
25. DM determines the cryptic and immunodominant fate of T cell epitopes.
Nanda NK; Sant AJ
J Exp Med; 2000 Sep; 192(6):781-8. PubMed ID: 10993909
[TBL] [Abstract][Full Text] [Related]
26. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.
Sadovnikova E; Zhu X; Collins SM; Zhou J; Vousden K; Crawford L; Beverley P; Stauss HJ
Int Immunol; 1994 Feb; 6(2):289-96. PubMed ID: 7512375
[TBL] [Abstract][Full Text] [Related]
27. Virus and cytotoxic T lymphocytes: crucial role of viral peptide secondary structure in major histocompatibility complex class I interactions.
Gairin JE; Oldstone MB
J Virol; 1993 May; 67(5):2903-7. PubMed ID: 7682632
[TBL] [Abstract][Full Text] [Related]
28. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone.
Zügel U; Schoel B; Kaufmann SH
J Immunol; 1994 Nov; 153(9):4070-80. PubMed ID: 7523514
[TBL] [Abstract][Full Text] [Related]
29. Interaction of an immunodominant epitope with Ia molecules in T-cell activation.
Adorini L; Sette A; Buus S; Grey HM; Darsley M; Lehmann PV; Doria G; Nagy ZA; Appella E
Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5181-5. PubMed ID: 2455895
[TBL] [Abstract][Full Text] [Related]
30. A molecular basis for how a single TCR interfaces multiple ligands.
Boesteanu A; Brehm M; Mylin LM; Christianson GJ; Tevethia SS; Roopenian DC; Joyce S
J Immunol; 1998 Nov; 161(9):4719-27. PubMed ID: 9794402
[TBL] [Abstract][Full Text] [Related]
31. Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides.
Melief CJ; Kast WM
Ciba Found Symp; 1994; 187():97-104; discussion 104-12. PubMed ID: 7796678
[TBL] [Abstract][Full Text] [Related]
32. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100.
van Stipdonk MJ; Badia-Martinez D; Sluijter M; Offringa R; van Hall T; Achour A
Cancer Res; 2009 Oct; 69(19):7784-92. PubMed ID: 19789338
[TBL] [Abstract][Full Text] [Related]
33. Processing of endogenously synthesized hen egg-white lysozyme retained in the endoplasmic reticulum or in secretory form gives rise to a similar but not identical set of epitopes recognized by class II-restricted T cells.
Adorini L; Guéry JC; Fuchs S; Ortiz-Navarrete V; Hämmerling GJ; Momburg F
J Immunol; 1993 Oct; 151(7):3576-86. PubMed ID: 7690807
[TBL] [Abstract][Full Text] [Related]
34. In vivo CTL immunity can be elicited by in vitro reconstituted MHC/peptide complex.
Sakita I; Hörig H; Sun R; Wang F; Nathenson SG
J Immunol Methods; 1996 Jun; 192(1-2):105-15. PubMed ID: 8699005
[TBL] [Abstract][Full Text] [Related]
35. Few peptides dominate cytotoxic T lymphocyte responses to single and multiple minor histocompatibility antigens.
Yin L; Poirier G; Neth O; Hsuan JJ; Totty NF; Stauss HJ
Int Immunol; 1993 Sep; 5(9):1003-9. PubMed ID: 7694638
[TBL] [Abstract][Full Text] [Related]
36. Mapping of epitopes recognized by alloreactive cytotoxic T lymphocytes using inhibition by MHC peptides.
Heath WR; Vitiello A; Sherman LA
J Immunol; 1989 Sep; 143(5):1441-6. PubMed ID: 2474598
[TBL] [Abstract][Full Text] [Related]
37. A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells.
Gallimore A; Hombach J; Dumrese T; Rammensee HG; Zinkernagel RM; Hengartner H
Eur J Immunol; 1998 Oct; 28(10):3301-11. PubMed ID: 9808199
[TBL] [Abstract][Full Text] [Related]
38. The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules.
Hudrisier D; Oldstone MB; Gairin JE
Virology; 1997 Jul; 234(1):62-73. PubMed ID: 9234947
[TBL] [Abstract][Full Text] [Related]
39. An immunodominant epitope present in multiple class I MHC molecules and recognized by cytotoxic T lymphocytes.
Mann DW; McLaughlin-Taylor E; Wallace RB; Forman J
J Exp Med; 1988 Jul; 168(1):307-24. PubMed ID: 2456370
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL.
Kuhröber A; Schirmbeck R; Reimann J
Eur J Immunol; 1994 May; 24(5):1172-80. PubMed ID: 7514132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
